[go: up one dir, main page]

MX2022002312A - Composicion farmaceutica para tratar cancer utilizada para un paciente que tiene un marcador genetico especifico. - Google Patents

Composicion farmaceutica para tratar cancer utilizada para un paciente que tiene un marcador genetico especifico.

Info

Publication number
MX2022002312A
MX2022002312A MX2022002312A MX2022002312A MX2022002312A MX 2022002312 A MX2022002312 A MX 2022002312A MX 2022002312 A MX2022002312 A MX 2022002312A MX 2022002312 A MX2022002312 A MX 2022002312A MX 2022002312 A MX2022002312 A MX 2022002312A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
patient
cancer treatment
specific gene
gene marker
Prior art date
Application number
MX2022002312A
Other languages
English (en)
Inventor
Hitoshi Endou
Masuhiro Yoshitake
Yoshinori Bamba
Tokiko Suzuki
Original Assignee
J Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J Pharma Co Ltd filed Critical J Pharma Co Ltd
Publication of MX2022002312A publication Critical patent/MX2022002312A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se proporciona una composición farmacéutica que comprende O-(5-amino-2-fenilbenzoxazol-7-il)metil-3,5-dicloro-L-tirosina, o una sal farmacéuticamente aceptable de la misma, para uso en el tratamiento de una enfermedad cancerosa en un sujeto, la composición farmacéutica se administra al sujeto que tiene un gen NAT2 tipo no rápido (lento y/o intermedio).
MX2022002312A 2019-08-30 2020-08-31 Composicion farmaceutica para tratar cancer utilizada para un paciente que tiene un marcador genetico especifico. MX2022002312A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019158681 2019-08-30
PCT/JP2020/032828 WO2021040042A1 (ja) 2019-08-30 2020-08-31 特定の遺伝子マーカーを有する患者に用いるがん治療用の医薬組成物

Publications (1)

Publication Number Publication Date
MX2022002312A true MX2022002312A (es) 2022-06-02

Family

ID=74684222

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022002312A MX2022002312A (es) 2019-08-30 2020-08-31 Composicion farmaceutica para tratar cancer utilizada para un paciente que tiene un marcador genetico especifico.
MX2022002316A MX2022002316A (es) 2019-08-30 2020-08-31 Composicion farmaceutica utilizada para un paciente que tiene un marcador genetico especifico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022002316A MX2022002316A (es) 2019-08-30 2020-08-31 Composicion farmaceutica utilizada para un paciente que tiene un marcador genetico especifico.

Country Status (10)

Country Link
US (2) US20220288035A1 (es)
EP (2) EP4023298A4 (es)
JP (3) JPWO2021040043A1 (es)
KR (2) KR20220054312A (es)
CN (3) CN114364381A (es)
BR (2) BR112022003220A2 (es)
CA (2) CA3152367A1 (es)
MX (2) MX2022002312A (es)
TW (3) TW202535373A (es)
WO (2) WO2021040042A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110945361B (zh) * 2017-11-07 2024-01-09 J制药股份有限公司 抗pd-1/pd-l1抗体疗法显效性的预测和提高方法以及评价癌症恶性程度的方法
MX2020006678A (es) 2017-12-28 2020-08-31 J Pharma Co Ltd Terapia para cancer.
TW202434224A (zh) 2023-01-16 2024-09-01 日商Ｊ製藥股份有限公司 膽道癌治療劑
WO2025197131A1 (ja) * 2024-03-18 2025-09-25 コーデックケミカル株式会社 非ヒト哺乳動物のがんの治療剤
CN118853874B (zh) * 2024-09-25 2025-02-28 山东大学齐鲁医院 N-乙酰转移酶10或其编码基因作为靶点在制备治疗银屑病药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074599A2 (en) * 2004-01-30 2005-08-18 Chemgenex Pharmaceuticals, Inc. Naphthalimide dosing by n-acetyl transferase genotyping
JP2007209286A (ja) * 2006-02-10 2007-08-23 Sutaagen:Kk Ｓｔ合剤の副作用の危険性の判定方法
WO2008081537A1 (ja) 2006-12-28 2008-07-10 Human Cell Systems, Inc. Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体、それを含有するｌａｔ１阻害活性剤及びその製造方法
JP5470665B1 (ja) * 2013-08-20 2014-04-16 ジェイファーマ株式会社 免疫抑制剤
CN105392498A (zh) * 2014-05-15 2016-03-09 J制药股份有限公司 抗恶性肿瘤剂组合物
JP6755457B2 (ja) * 2016-04-08 2020-09-16 株式会社Ｃｉｃｓ 合成アミノ酸の癌細胞内取り込みを保持する修飾法と正常細胞を保護する中性子捕捉療法
KR20210072770A (ko) * 2018-10-02 2021-06-17 조지타운 유니버시티 염증성 신경계 장애를 치료하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
TW202535373A (zh) 2025-09-16
BR112022002894A2 (pt) 2022-05-10
CA3152369A1 (en) 2021-03-04
US20220288036A1 (en) 2022-09-15
CN114364381A (zh) 2022-04-15
JP2021121634A (ja) 2021-08-26
CN114340621A (zh) 2022-04-12
JPWO2021040043A1 (es) 2021-03-04
CN119564680A (zh) 2025-03-07
EP4023298A4 (en) 2024-01-03
MX2022002316A (es) 2022-06-02
US20220288035A1 (en) 2022-09-15
JP6894155B2 (ja) 2021-06-23
WO2021040043A1 (ja) 2021-03-04
BR112022003220A2 (pt) 2022-05-17
KR20220054312A (ko) 2022-05-02
EP4023298A1 (en) 2022-07-06
KR20220054603A (ko) 2022-05-03
TW202122080A (zh) 2021-06-16
CA3152367A1 (en) 2021-03-04
WO2021040042A1 (ja) 2021-03-04
JP2021038214A (ja) 2021-03-11
TW202122081A (zh) 2021-06-16
EP4023296A1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
MX2022002312A (es) Composicion farmaceutica para tratar cancer utilizada para un paciente que tiene un marcador genetico especifico.
CL2023002497A1 (es) Uso de inhibidores de bet como tratamiento para la mielofibrosis
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
CO6251364A2 (es) Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
ECSP109934A (es) Compuesto - 946
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
MX2018012901A (es) Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CY1114215T1 (el) Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης
ME01133B (me) Kombinovana terapija sa peptidnim epoksiketonima
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2024004156A (es) Virus oncoliticos optimizados y usos de los mismos.
MY209484A (en) Cpg amphiphiles and uses thereof
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
CL2025001937A1 (es) Arn terapéutico para el cáncer positivo para vph
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
MX2021000127A (es) Formulaciones de un inhibidor de axl/mer.
SE0300098D0 (sv) Use of cyclin D1 inhibitors
MX2024005237A (es) Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo.
BR112023022647A2 (pt) Derivado de 7-nitro-8-hidroxiquinolina, método de preparação do mesmo e uso médico do mesmo